Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trialPatrick Schöffski, Shreyaskumar Patel, David R. D’Adamo et al.|The Lancet|2016Cited by 766
Improved quality of life for romiplostim‐treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo‐controlled trialsJames N. George, Martin R. Schipperus, Susan D. Mathias et al.|British Journal of Haematology|2008Cited by 146
Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update.David J. Kuter, Janet L. Nichol, James B. Bussel et al.|Blood|2006Cited by 30
Evaluation of AMG 531 Efficacy in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in a Randomized Placebo-Controlled Phase 3 Study.Terry Gernsheimer, Janet L. Nichol, Vinod Pullarkat et al.|Blood|2007Cited by 6
Evaluation of Bleeding and Thrombotic Events during Long-Term Use of Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura.Michael D. Tarantino, Terry Gernsheimer, James N. George et al.|Blood|2008Cited by 5